Segulah IV has entered into an agreement to sell 100 per cent of the shares in Medstop Group to Oriola-KD.   The transaction, which is subject to the approvals of the Swedish Competition Authority (Konkurrensverket) and the Swedish Medical Products Agency (Läkemedelsverket), values the company to SEK1,460m including an estimate

Maven Capital Partners, a private equity and alternative asset manager, has completed the acquisition of Fundamental Tracker Investment Management (FTIM) from City of London Group.   The primary business of FTIM is The Munro UK Dividend Fund, a passive tracker OEIC which will be rebranded under the Maven name in

A consortium led by iCON Infrastructure Partners II and including EEA and 2OC has entered into agreements to fund and construct an environmentally friendly 19 MW CHP facility that will provide heat and power under long-term contracts to Thames Water Utilities and National Grid.   The facility is located in

GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, has closed a EUR32m Series A financing.   The financing was co-led by Novartis Venture Fund, Abingworth, Versant Ventures and Index Ventures.   GenSight will use the funds to develop a gene replacement therapy for

There were 665 private equity-backed buyout deals announced globally in Q1 2013, valued at a total of USD87bn, a 112 per cent increase from the USD41bn in the same quarter last year, according to Preqin. However, the number of deals fell from 770 in Q4 2012 to 665 in the

North Castle Partners and its co-investors have completed an investment of growth capital in Ignite USA, a developer and marketer of reusable, environmentally friendly thermal mugs and hydration bottles.   North Castle is a private equity firm focused on investments in consumer-driven companies that promote healthy, active and sustainable living.